Can Peptide Pills Finally Challenge Cholesterol Injections?

Phase 3 data suggest oral peptide drugs could rival injectables for lowering LDL cholesterol, pointing to a future shift if approvals and safety milestones are met

30 Jan 2026

A quiet shift is underway in cardiovascular medicine, and it could change how patients take some of the most powerful cholesterol drugs on the market.

New Phase 3 results from Merck are adding momentum to a long-held goal in drug development: turning peptide therapies into pills. For decades, these medicines have been trapped in syringe form, prized for their precision but limited by how the body absorbs them.

Merck’s oral cholesterol candidate targets LDL, often called bad cholesterol. In high-risk patients already on standard treatments like statins, the pill delivered LDL reductions approaching those seen with injectable PCSK9 drugs. That matters because injections have defined the top tier of cholesterol care, even as their use has lagged.

The delivery method is the real headline. Peptides are fragile molecules. They tend to break down in the digestive tract, which is why injections became the default. Cracking the oral code has been a technical challenge that defeated many promising programs.

If that barrier is falling, the ripple effects could be large. Injectable cholesterol drugs work well, but many patients never start them or stop early. Cost, clinic visits, and simple needle fatigue all play a role. A daily pill fits more naturally into routine care, especially for people who still miss their cholesterol goals on statins alone.

The implications stretch beyond heart disease. Drugmakers across the industry are exploring oral peptide platforms, eyeing conditions from diabetes to inflammatory disorders. A win in cholesterol would strengthen confidence that the approach can travel.

None of this is settled yet. Regulators still need to weigh safety, durability, and real-world outcomes. Manufacturing peptide pills at scale also remains complex.

Still, the latest data feel like more than a technical milestone. They suggest a future where some of today’s injectable biologics may eventually come in a bottle, not a box of syringes. That would be a meaningful shift for patients and for the drug industry alike.